Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis

Journal of Neurochemistry

Volumn 88, Issue 3, 2004, Pages 576-582

  Klivenyi, Peter ^a   Kiaei, Mahmoud ^a   Gardian, Gabrielle ^a   Calingasan, Noel Y ^a   Beal, M Flint ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Creatine; Cyclooxygenase; Free radicals; Mitochondria; Prostaglandin E2; Superoxide dismutase

Indexed keywords

CELECOXIB; CREATINE; CYCLOOXYGENASE 2 INHIBITOR; FREE RADICAL; PROSTAGLANDIN E2; ROFECOXIB; SUPEROXIDE DISMUTASE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN MITOCHONDRION; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG MECHANISM; DRUG POTENTIATION; INFLAMMATION; MOTONEURON; MOTOR PERFORMANCE; MOUSE; NEUROPROTECTION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SPINAL CORD VENTRAL HORN; SURVIVAL; TRANSGENIC MOUSE; WEIGHT REDUCTION;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; CREATINE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; ISOENZYMES; MALE; MICE; MICE, TRANSGENIC; NEUROPROTECTIVE AGENTS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SUPEROXIDE DISMUTASE;

ANIMALIA; MUS MUSCULUS;

EID: 0942287666     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2003.02160.x     Document Type: Article

References (53)

1. Adams J., Collaco-Moraes Y. and de Belleroche J. (1996) Cyclooxygenase-2 induction in cerebral cortex: an intracellular response to synaptic excitation. J. Neurochem. 66, 6-13.
2. Almer G., Vukosavic S., Romero N. and Przedborski S. (1999) Inducible nitric oxide synthase up-regulation in a transgenic mouse model of familial amyotrophic lateral sclerosis. J. Neurochem. 72, 2415-2425.
3. Almer G., Guegan C., Teismann P., Naini A., Rosoklija G., Hays A. P., Chen C. and Przedborski S. (2001) Increased expression of the proinflammatory enzyme cyclooxygenase-2 in amyotrophic lateral sclerosis. Ann. Neurol. 49, 176-185.
4. 2 in CSF from amyotrophic lateral sclerosis patients. Neurology 56, A463.
5. Andreassen O. A., Jenkins B. G., Dedeoglu A., Ferrante K. L., Bogdanov M. B., Kaddurah-Daouk R. and Beal M. F. (2001) Increases in cortical glutamate concentration in transgenic amyotrophic lateral sclerosis mice are attenuated by creatine supplementation. J. Neurochem. 77, 383-390.
6. Araki E., Forster C., Dubinsky J. M., Ross M. E. and Iadecola C. (2001) Cyclooxygenase-2 inhibitor ns-398 protects neuronal cultures from lipopolysaccharide-induced neurotoxicity. Stroke 32, 2370-2375.
7. Bezzi P., Carmignoto G., Pasti L., Vesce S., Rossi D., Rizzini B. L., Pozzan T. and Volterra A. (1998) Prostaglandins stimulate calcium-dependent glutamate release in astrocytes. Nature 391, 281-285.
8. Bezzi P., Domercq M., Brambilla L. et al. (2001) CXCR4-activated astrocyte glutamate release via TNFalpha: amplification by microglia triggers neurotoxicity. Nat. Neurosci. 4, 702-710.
9. Browne S. E., Yang L., Fuller S. W. et al. (2001) Metabolic changes precede pathologic changes in the G93A mouse model of familial amyotrophic lateral sclerosis (ALS). Soc. Neurosci. 27, 1512.
10. Cao C., Matsumura K., Yamagata K. and Watanabe Y. (1995) Induction by lipopolysaccharide of cyclooxygenase-2 mRNA in rat brain; its possible role in the febrile response. Brain Res. 697, 187-196.
11. Drachman D. B. and Rothstein J. D. (2000) Inhibition of cyclooxygenase-2 protects motor neurons in an organotypic model of amyotrophic lateral sclerosis. Ann. Neurol. 48, 792-795.
12. Drachman D. B., Frank K., Dykes-Hoberg M., Teismann P., Almer G., Przedborski S. and Rothstein J. D. (2002) Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann. Neurol. 52, 771-778.
13. Elliott J. L. (2001) Cytokine upregulation in a murine model of familial amyotrophic lateral sclerosis. Brain Res. Mol. Brain Res. 95, 172-178.
14. Ferrante R. J., Andreassen O. A., Dedeoglu A., Ferrante K. L., Jenkins B. G., Hersch S. M. and Beal M. F. (2002) Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease. J. Neurosci. 22, 1592-1599.
15. Fitzgerald G. A. and Patrono C. (2001) The coxibs, selective inhibitors of cyclooxygenase-2. N Engl. J. Med. 345, 433-442.
16. Friedlander R. M., Brown R. H., Gagliardini V., Wang J. and Yuan J. (1998) Inhibition of ICE slows ALS in mice. Nature 392, 560.
17. Ghezzi P., Bernardini R., Giuffrida R., Bellomo M., Manzoni C., Comoletti D., Di Santo E., Beningi F. and Mennini T. (1998) Tumor necrosis factor is increased in the spinal cord of an animal model of motor neuron degeneration. Eur. Cytokine Netw. 9, 139-144.
18. Groeneveld J., Veldink J. H., van der Tweel I., Kalmijn S., Beijer C., de Visser M., Wokke J. H., Franssen H. and van den Berg L. H. (2003) A randomized trial of creatine in amyotrophic lateral sclerosis. Ann. Neurol. 53, 437-445.
19. Gurney M. E. (1994) Transgenic-mouse model of amyotrophic lateral sclerosis. N. Engl. J. Med. 331, 1721-1722.
20. Gurney M. E., Fleck T. J., Himes C. S. and Hall E. D. (1998) Riluzole preserves motor function in a transgenic model of familial amyotrophic lateral sclerosis. Neurology 50, 62-66.
21. Haenggeli C. and Kato C. (2002) Differential vulnerability of cranial motoneurons in mouse models with motor neuron degeneration. Neurosci. Lett. 2002, 39-43.
22. Hall E. D., Oostveen J. A. and Gurney M. E. (1998) Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia 23, 249-256.
23. Hemmer W. and Wallimann T. (1993) Functional aspects of creatine kinase in brain. Dev. Neurosci. 15, 249-260.
24. Hensley K., Floyd R. A., Gordon B., Mou S., Pye Q. N., Stewart C., West M. and Williamson K. (2002) Temporal patterns of cytokine and apoptosis-related gene expression in spinal cords of the G93-SOD1 mouse model of amyotrophic lateral sclerosis. J. Neurochem. 82, 365-374.
25. Hewett S. J., Uliasz T. F., Vidwans A. S. and Hewett J. A. (2000) Cyclooxygenase-2 contributes to N-methyl-D-aspartate-mediated neuronal cell death in primary cortical cell culture. J. Pharmacol. Exp. Ther. 293, 417-425.
26. Higgins C. M., Jung C., Ding H. and Xu Z. (2002) Mutant Cu, Zn superoxide dismutase that causes motoneuron degeneration is present in mitochondria in the CNS. J. Neurosci. 22, RC215.
27. Hirano A. (1996) Neuropathology of ALS: an overview. Neurology 47, S63-S66.
28. Ho L., Osaka H., Aisen P. S. and Pasinetti G. M. (1998) Induction of cyclooxygenase (COX)-2 but not COX-1 gene expression in apoptotic cell death. J. Neuroimmunol. 89, 142-149.
29. Iadecola C., Niwa K., Nogawa S., Zhao X., Nagayama M., Araki E., Morham S. and Ross M. E. (2001) Reduced susceptibility to ischemic brain injury and N-methyl-D-aspartate-mediated neurotoxicity in cyclooxygenase-2-deficient mice. Proc. Natl Acad. Sci. USA 98, 1294-1299.
30. Ilzecka J. (2003) Prostaglandin E2 is increased in amyotrophic lateral sclerosis patients. Acta Neurol. Scand. 108, 125-129.
31. Kelley K. A., Ho L., Winger D., Freire-Moar J., Borelli C. B., Aisen P. S. and Pasinetti G. M. (1999) Potentiation of excitotoxicity in transgenic mice overexpressing neuronal cyclooxygenase-2. Am. J. Pathol. 155, 995-1004.
32. Klivenyi P., Ferrante R. J., Matthews R. T., Bogdanov M. B., Klein A. M., Andreassen O. A., Mueller G., Wermer M., Kaddurah-Daouk R. and Beal M. F. (1999) Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat. Med. 5, 347-350.
33. Kong J. and Xu Z. (1998) Massive mitochondrial degeneration in motor neurons triggers the onset of amyotrophic lateral sclerosis in mice expressing a mutant SOD1. J. Neurosci. 18, 3241-3250.
34. Kostic V., Gurney M. E., Deng H. X., Siddique T., Epstein C. J. and Przedborski S. (1997) Midbrain dopaminergic neuronal degeneration in a transgenic mouse model of familial amyotrophic lateral sclerosis. Ann. Neurol. 41, 497-504.
35. Kriz J., Gowing C. and Julien J. P. (2003) Efficient three-drug cocktail for disease induced by mutant superoxide dismutase. Ann. Neurol. 53, 429-436.
36. Li M., Ona V. O., Guegan C. et al. (2000) Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science 288, 335-339.
37. Mirjany M., Ho L. and Pasinetti G. M. (2002) Role of cyclooxygenase-2 in neuronal cell cycle activity and glutamate-mediated excitotoxicity. J. Pharmacol. Exp. Ther. 301, 494-500.
38. Nguyen M. D., Julien J. P. and Rivest S. (2001) Induction of proinflammatory molecules in mice with amyotrophic lateral sclerosis: no requirement for proapoptotic interleukin-1beta in neurodegeneration. Ann. Neurol. 50, 630-639.
39. O'Banion M. K., Miller J. C., Chang J. W., Kaplan M. D. and Coleman P. D. (1996) Interleukin-1 beta induces prostaglandin G/H synthase-2 (cyclooxygenase-2) in primary murine astrocyte cultures. J. Neurochem. 66, 2532-2540.
40. Olsen M. K., Roberds S. L., Ellerbrock B. R., Fleck T. J., McKinley D. K. and Gurney M. E. (2001) Disease mechanisms revealed by transcription profiling in SOD1-G93A transgenic mouse spinal cord. Ann. Neurol. 50, 730-740.
41. Planas A. M., Soriano M. A., Justicia C. and Rodriguez-Farre E. (1999) Induction of cyclooxygenase-2 in the rat brain after a mild episode of focal ischemia without tissue inflammation or neural cell damage. Neurosci. Lett. 275, 141-144.
42. Pompl P. N., Ho L., Bianchi M., McManus T., Qin W. and Pasinetti G. M. (2003) A therapeutic role for cyclooxygenase-2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. FASEB J. February 5 (epub ahead of print).
43. Rosen D. R., Siddique T., Patterson D. et al. (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362, 59-62.
44. Schiffer D., Cordera S., Cavalla P. and Migheli A. (1996) Reactive astrogliosis of the spinal cord in amyotrophic lateral sclerosis. J. Neurol. Sci. 139, 27-33.
45. Sekizawa T., Openshaw H., Ohbo K., Sugamura K., Itoyama Y. and Niland J. C. (1998) Cerebrospinal fluid interleukin 6 in amyotrophic lateral sclerosis: immunological parameter and comparison with inflammatory and non-inflammatory central nervous system diseases. J. Neurol. Sci. 154, 194-199.
46. Teismann P. and Ferger B. (2001) Inhibition of the cyclooxygenase isoenzymes COX-1 and COX-2 provide neuroprotection in the MPTP-mouse model of Parkinson's disease. Synapse 39, 167-174.
47. Tocco G., Freire-Moar J., Schreiber S. S., Sakhi S. H., Aisen P. S. and Pasinetti G. M. (1997) Maturational regulation and regional induction of cyclooxygenase-2 in rat brain: implications for Alzheimer's disease. Exp. Neurol. 144, 339-349.
48. Wendt S., Dedeoglu A., Speer O., Wallimann T., Beal M. F. and Andreassen O. A. (2002) Reduced creatine kinase activity in transgenic amyotrophic lateral sclerosis mice. Free Radic. Biol. Med. 32, 920-926.
49. Wong P. C., Pardo C. A., Borchelt D. R., Lee M. K., Copeland N. G., Jenkins N. A., Sisodia S. S., Cleveland D. W. and Price D. L. (1995) An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 14, 1105-1116.
50. Xu C. J., Klunk W. E., Kanfer J. N., Xiong Q., Miller G. and Pettegrew J. W. (1996) Phosphocreatine-dependent glutamate uptake by synaptic vesicles. J. Biol. Chem. 271, 13 435-13 440.
51. Yasojima K., Tourtellotte W. W., McGeer E. G. and McGeer P. L. (2001) Marked increase in cyclooxygenase-2 in ALS spinal cord: implications for therapy. Neurology 57, 952-956.
52. Yoshihara T., Ishigaki S., Yamamoto M., Liang Y., Niwa J., Takeuchi H., Doyu M. and Sobue G. (2002) Differential expression of inflammation and apoptosis-related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis. J. Neurochem. 80, 158-167.
53. Zhang W., Narayanan M. and Friedlander R. M. (2003) Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Ann. Neurol. 53, 267-270.